PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/537, 47/36	A1	(11) International Publication Number: WO 00/18406
		(43) International Publication Date: 6 April 2000 (06.04.00)

(21) International Application Number: PCT/EP99/07117

(22) International Filing Date: 24 September 1999 (24.09.99)

(30) Priority Data:
60/102,112 28 September 1998 (28.09.98) US

(71) Applicant *(for all designated States except US)*: GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: BALIK, Samuel, Bruce [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US).

(74) Agent: REED, Michael, A.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ORAL DOSAGE FORMULATIONS COMPRISING (2S,3S,5R) -2-(3,5- DIFLUOROPHENYL) -3,5-DIMETHYL -2-MORPHOLINOL AND AN EFFECTIVE STABILIZING AMOUNT OF ALGINIC ACID

(57) Abstract

This invention provides discrete oral dosage forms, typically tablets or capsules, containing (2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol or a physiologically acceptable salt or solvate thereof, or a solvate of said salt, and an effective stabilizing amount of alginic acid. These dosage forms are useful for preventing or treating attention deficit hyperkinetic disorder or depression, or in the treatment of addiction to nicotine-containing products, especially tobacco-containing products, such as aiding in smoking cessation.